Clinical Dilemmas in Non–Alcoholic Fatty Liver Disease

Professor Roger Williams CBE, runs the Institute of Hepatology at UCL, and is a twice former president of EASL. He has authored an incredible 2100 journal articles. Despite advancing years, he is still actively involved in clinical research -- 340 articles in the past ten years, and analysis by ISI shows him to be one of the most influential researchers in his field. The award of a CBE for services to medicine recognised his major contribution to the study of liver disorders over 25 years including leading the team who performed the first ever UK liver transplant. He also performed George Best's controversial liver transplant in 2002. Prof Williams has had many awards, medals, honorary fellowships, and in 2006 was included by HRH The Queen in a celebration at Buckingham Palace to honour those who continue to contribute to public service beyond the age of 65yrs. He was made a Fellow of King's College London in 1992 and an Honorary Fellowship from UCL was conferred on him in 2008, in recognition of his distinguished career and outstanding service to UCL. Professor Simon Taylor-Robinson joined the Department of Medicine at Imperial College London in 1997, having previously been Senior Registrar in Gastroenterology and Hepatology at Hammersmith Hospital. He was awarded the Sir Francis Avery Jones Gold Medal by the British Society of Gastroenterology in 1999 and the Young Investigator Award of the Liver Section of the European Gastroenterology Association in 1997. He is currently Director of the Imperial Clinical Research Facility at St Mary's Hospital, London.

List of contributors Preface Part I Nature of the condition Chapter 1 Hype or harm from Fatty Liver Disease? Stephen H Caldwell and Curt Argo Chapter 2 Worldwide problem. Geoffrey Farrell and Philip Newsome Chapter 3 Is insulin resistance the key motive for NAFLD? Desmond Johnston Chapter 4 Progression to cirrhosis is more likely in children with NAFLD? Anil Dhawan Chapter 5 NAFLD as cause of cryptogenic cirrhosis? Jay Lefkowitch Chapter 6 Is NAFLD different in absence of Metabolic Syndrome? Yusuf Yilmaz Chapter 7 Occurrence of noncirrhotic HCC in NAFLD Stephen Harrison and Dawn Torres Part II Factors in Disease Progression Chapter 8 Fibrosis progression molecular pathways all important? Anna-Mae Diehl and Dr Wing-Kin Syn Chapter 9 Can fatty liver of NAFLD be distinguished from that of Alcoholic Liver Disease? David Kleiner and Elizabeth Brunt Chapter 10 Are inflammasomes and intestinal microbiota relevant in disease progression to NASH? M. Bilal Siddiqui, M. Shadab Siddiqui and Arun Sanyal Chapter 11 Can genetic influence in Non-Alcoholic Fatty Liver Disease be ignored? Quentin Anstee Chapter 12 Is there a mechanistic link between hepatic steatosis and cardiac rather than liver events? Soo Lim Part III Diagnosis and Scoring Chapter 13 Is there a best method for diagnosis of NAFLD? Vlad Ratziu Chapter 14 Choice of non-invasive blood tests and FibroScan Massimo Pinzani and Manolis Tsocatzis Chapter 15 Are the guidelines - AASLD, IASL, EASL and BSG of help? Jean-Francois Dufour Chapter 16 How to choose from different imaging modalities and screening techniques Hero Hussain Chapter 17 Are the pros outweighed by the cons of obtaining a liver biopsy? Simon Taylor-Robinson and Jeremy Cobbold Chapter 18 Screening for NAFLD in high risk population Nader Lessan Part IV Value of treatment measures Chapter 19 Balancing calorie restriction, exercise and weight reduction Nicholas Finer Chapter 20 Should Physicians be prescribing, or patients self-medicating with Orlistat, Vitamin E, Vitamin D, insulin antagonist, Trental and coffee? Brent Neuschwander-Tetri and Haripriya Maddur Chapter 21 Does improvement in hepatic steatosis have a significant favourable effect on the Metabolic Syndrome, including diabetes? Jukka Westerbacka Chapter 22 What are the dangers as well as the true benefits of bariatric surgery? Andrew Jenkinson Chapter 23 Liver transplantation; what can it offer? Roger Williams Part V What does the future hold? Chapter 24 Molecular antagonists, leptin or other hormones in supplementing environmental factors? Jeremy Tomlinson Chapter 25 Use of antifibrotic agents in clinical practice Jonathan Fallowfield Chapter 26 Better understanding of early development and material influence? Jude Oben Chapter 27 Defining the role of Metabolic Physician Nicholas Finer Index